Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Fused bicyclic compound

A technology for fused bicyclic compounds, applied in the field of new fused bicyclic compounds

Inactive Publication Date: 2010-08-18
MITSUBISHI TANABE PHARMA CORP
View PDF5 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there are no reports on fused bicyclic compounds such as the compounds of the present invention (1,3-benzoxazine derivatives or benzopyran derivatives) having MR modulating activity (such as MR antagonistic activity)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Fused bicyclic compound
  • Fused bicyclic compound
  • Fused bicyclic compound

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Disclosed is a novel fused bicyclic compound [I] shown below, which has affinity for a mineralcorticoid receptor (MR) and is useful as an anti-hypertensive agent or the like. Specifically disclosed is a compound represented by the formula [I] or a pharmacologically acceptable salt thereof. [I] wherein the ring A represents a benzene ring which is fused with the adjacent heterocyclic 6-membered ring and has a substituent R1, and which may have a substituent other than R1; R1 represents an alkylsulfonylamino group or the like; R2 and R3 (a) independently represent a hydrogen, an alkyl or a substituted or unsubstituted aryl, (b) together form an oxo, or (c) together with the adjacent carbon atom, form a cycloalkyl; X represents =N-, =C(R4)- or -CH(R4)-; R4 represents (a) a hydrogen, (b) a cyano, (c) a halogen, (d) an alkyl, (e) an alkenyl, (f) a cycloalkyl, (g) an alkanoyl, (h) a carbamoyl or (i) a cycloalkenyl; Ar represents a substituted or unsubstituted aromatic cyclic group; and a dotted line means the presence or absence of a double bond.

Description

technical field The present invention relates to novel fused bicyclic compounds having an affinity for the mineralocorticoid receptor (MR) which are useful in the treatment and / or prophylaxis of diseases or clinical conditions associated with said receptor. Background technique Physiologically active hydrophobic substances having a low molecular weight such as steroid hormones demonstrate their actions via the respective nuclear receptors as their ligands. A group of steroid hormone nuclear receptors forms an inherited superfamily and controls, ie, activates or represses, target gene expression at the transcriptional level by functioning as ligand-dependent transcription factors. Steroid hormone receptors include mineralocorticoid receptor (MR), glucocorticoid receptor (GR), androgen receptor (AR), estrogen receptor (ER) and progesterone receptor (PR). Steroid hormones such as mineralocorticoids (aldosterone) or glucocorticoids (cortisone, etc.), which are ligands for rece...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07D265/16A61P9/12A61P43/00C07D311/58C07D413/04A61P9/04A61K31/352A61K31/353A61K31/536A61P9/00
CPCC07D413/04C07D311/96C07D405/14C07D265/16C07D311/58C07D311/20A61P5/46A61P9/00A61P9/04A61P9/06A61P9/12A61P43/00
Inventor 高桥阳一淡井信将赤塚英则川口隆行饭岛彻
Owner MITSUBISHI TANABE PHARMA CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products